Get the Stockscreener App
0.306
1.29%
-0.004
Leap Therapeutics Inc stock is traded at $0.306, with a volume of 212.90K.
It is down -1.29% in the last 24 hours and up +3.27% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.31
Open:
$0.3007
24h Volume:
212.90K
Relative Volume:
0.18
Market Cap:
$12.68M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.1832
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-14.93%
1M Performance:
+3.27%
6M Performance:
-45.37%
1Y Performance:
-85.57%
1-Day Range:
$0.2848
$0.3082
1-Week Range:
$0.2848
$0.375
52-Week Range:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.306 | 12.85M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
How Leap Therapeutics Inc. stock performs during market volatilityAI Pattern Recognition and Trade Prediction - Newser
Predicting Leap Therapeutics Inc. trend using moving averagesSmart Trade Mapping with Entry Details - Newser
How to integrate Leap Therapeutics Inc. into portfolio analysis toolsDay Trading Plan with Entry Risk Management - Newser
Momentum divergence signals in Leap Therapeutics Inc. chartAlgorithmic Prediction of Market Breakouts - Newser
What makes Leap Therapeutics Inc. stock price move sharplyStrong Buy Opportunity with Volume Support - Newser
Using data filters to optimize entry into Leap Therapeutics Inc.Weekly Market Direction and Sector Summary - Newser
Why is Leap Therapeutics Inc. stock attracting strong analyst attentionSwing Trade Updates To Watch Now - jammulinksnews.com
Combining price and volume data for Leap Therapeutics Inc.Smart Chart Forecasting with AI Algorithms - Newser
Is Leap Therapeutics Inc. stock reversal real or fakeAlgorithmic Prediction of Market Breakouts - Newser
Does Leap Therapeutics Inc. qualify in momentum factor screeningBear Market Safe Zone Technical Analysis - Newser
Will earnings trigger a reversal in Leap Therapeutics Inc.Free Verified Signal From Chart Patterns - Newser
Is Leap Therapeutics Inc. a candidate for recovery playMarket Ready Picks with Technical Support - Newser
Will Leap Therapeutics Inc. stock recover after recent dropReal-Time Entry Forecast with Accuracy Metrics - Newser
What’s next for Leap Therapeutics Inc. stock priceEntry Zone Strategy for Consistent Profit Shared - metal.it
Why Leap Therapeutics Inc. stock attracts strong analyst attentionShort-Term Sector Movement Forecast Generator - Newser
Analyzing drawdowns of Leap Therapeutics Inc. with statistical toolsFree Low Risk Buy Zone Opportunity Watch - Newser
Analyzing Leap Therapeutics Inc. with multi timeframe chartsDay Trading Plan with Entry Risk Management - Newser
Leap Therapeutics Inc.’s Price Action Aligns with Quant SignalsReal Trader Watchlist of Hot Stocks Released - metal.it
When is the best time to exit Leap Therapeutics Inc.Long-Term Signal Tracking and Profit Summary - Newser
Analysts Backtest Strategies on Leap Therapeutics Inc. With Promising ResultsStock Market Entry Timing Signals Revealed - metal.it
Does Leap Therapeutics Inc. stock pay reliable dividendsInvestment Strategy With Predictable Gains Outlined - metal.it
Is it the right time to buy Leap Therapeutics Inc. stockStock Market Entry Points To Watch Now - jammulinksnews.com
When is Leap Therapeutics Inc. stock expected to show significant growthLow Risk Recommendation With High Returns - jammulinksnews.com
What is Leap Therapeutics Inc. company’s growth strategyHigh-yield capital appreciation - jammulinksnews.com
What catalysts could drive Leap Therapeutics Inc. stock higher in 2025Capital growth strategies that work - jammulinksnews.com
What are the latest earnings results for Leap Therapeutics Inc.Unmatched market gains - jammulinksnews.com
How does Leap Therapeutics Inc. generate profit in a changing economyUnprecedented profits - jammulinksnews.com
Does Leap Therapeutics Inc. stock perform well during market downturnsAccess exclusive market insights for free - jammulinksnews.com
Is Leap Therapeutics Inc. a growth stock or a value stockAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
What institutional investors are buying Leap Therapeutics Inc. stockMaximize portfolio growth with expert advice - jammulinksnews.com
Published on: 2025-07-28 03:31:39 - jammulinksnews.com
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):